Zevra Therapeutics (ZVRA) Long-Term Deferred Tax (2014 - 2019)

Zevra Therapeutics has reported Long-Term Deferred Tax for 6 years, with the latest figure at $67.7 million in Q4 2019.

• For the quarter ending Q4 2019, Long-Term Deferred Tax rose 12.2% year-over-year to $67.7 million; the trailing twelve-month figure through Dec 2019 stood at $67.7 million (up 12.2% YoY), and the FY2019 full-year result was $67.7 million, up 12.2% from the prior year.
• Long-Term Deferred Tax for Q4 2019 stood at $67.7 million, up from $60.4 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $67.7 million in Q4 2019, with the low at $29.1 million in Q4 2015.
• Historically, Long-Term Deferred Tax has averaged $49.9 million across 5 years, with a median of $48.9 million in 2016.
• Annual changes were most pronounced in 2016 — Long-Term Deferred Tax surged 67.9% — and 2017, when it declined 11.54%.
• Zevra Therapeutics' Long-Term Deferred Tax stood at $29.1 million in 2015, then jumped by 67.9% to $48.9 million in 2016, then retreated by 11.54% to $43.2 million in 2017, then jumped by 39.65% to $60.4 million in 2018, then grew by 12.2% to $67.7 million in 2019.
• The last three Long-Term Deferred Tax figures came in at $67.7 million (Q4 2019), $60.4 million (Q4 2018), and $43.2 million (Q4 2017), per Business Quant data.